These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 18034622)

  • 1. Measuring biomarkers to assess the therapeutic effects of PPAR agonists?
    Chinetti-Gbaguidi G; Staels B
    Pharmacogenomics; 2007 Nov; 8(11):1567-80. PubMed ID: 18034622
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Therapeutical effects of PPAR agonists assessed by biomarker modulation.
    Chinetti-Gbaguidi G; Fruchart JC; Staels B
    Biomarkers; 2005 Nov; 10 Suppl 1():S30-6. PubMed ID: 16298909
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Atherosclerosis and cardiovascular risk reduction with PPAR agonists.
    Kuusisto J; Andrulionyte L; Laakso M
    Curr Atheroscler Rep; 2007 Oct; 9(4):274-80. PubMed ID: 18173954
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Peroxisome proliferator-activated receptors in vascular biology-molecular mechanisms and clinical implications.
    Touyz RM; Schiffrin EL
    Vascul Pharmacol; 2006 Jul; 45(1):19-28. PubMed ID: 16782410
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PPAR agonists and the metabolic syndrome.
    Staels B
    Therapie; 2007; 62(4):319-26. PubMed ID: 17983557
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The roles of peroxisome proliferator-activated receptors in the metabolic syndrome.
    Mansour M
    Prog Mol Biol Transl Sci; 2014; 121():217-66. PubMed ID: 24373239
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PPARs as targets for the modulation of cardiovascular risk factors associated with the metabolic syndrome.
    Fernandez AZ
    Curr Opin Investig Drugs; 2004 Sep; 5(9):936-40. PubMed ID: 15503647
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Peroxisome proliferator-activated receptors as transcriptional nodal points and therapeutic targets.
    Brown JD; Plutzky J
    Circulation; 2007 Jan; 115(4):518-33. PubMed ID: 17261671
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Therapeutic roles of peroxisome proliferator-activated receptor agonists.
    Staels B; Fruchart JC
    Diabetes; 2005 Aug; 54(8):2460-70. PubMed ID: 16046315
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Healing the diabetic heart: modulation of cardiometabolic syndrome through peroxisome proliferator activated receptors (PPARs).
    Huang TH; Roufogalis BD
    Curr Mol Pharmacol; 2012 Jun; 5(2):241-7. PubMed ID: 22122453
    [TBL] [Abstract][Full Text] [Related]  

  • 11. New approach in the treatment of T2DM and metabolic syndrome (focus on a novel insulin sensitizer).
    Tjokroprawiro A
    Acta Med Indones; 2006; 38(3):160-6. PubMed ID: 17119268
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Insulin resistance and PPAR insulin sensitizers.
    Bhatia V; Viswanathan P
    Curr Opin Investig Drugs; 2006 Oct; 7(10):891-7. PubMed ID: 17086933
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PPAR agonists for the treatment of cardiovascular disease in patients with diabetes.
    Wilding JP
    Diabetes Obes Metab; 2012 Nov; 14(11):973-82. PubMed ID: 22443197
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Drug Insight: mechanisms of action and therapeutic applications for agonists of peroxisome proliferator-activated receptors.
    Gervois P; Fruchart JC; Staels B
    Nat Clin Pract Endocrinol Metab; 2007 Feb; 3(2):145-56. PubMed ID: 17237841
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PPAR agonists: multimodal drugs for the treatment of type-2 diabetes.
    Gross B; Staels B
    Best Pract Res Clin Endocrinol Metab; 2007 Dec; 21(4):687-710. PubMed ID: 18054742
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PPAR ligands: are they potential agents for cardiovascular disorders?
    Balakumar P; Rose M; Singh M
    Pharmacology; 2007; 80(1):1-10. PubMed ID: 17496434
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Significance of peroxisome proliferator-activated receptors in the cardiovascular system in health and disease.
    Robinson E; Grieve DJ
    Pharmacol Ther; 2009 Jun; 122(3):246-63. PubMed ID: 19318113
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Nuclear receptors PPAR as a drug target in metabolic disorders].
    Stolarczyk M; Gutman W; Derlacz RA
    Postepy Biochem; 2011; 57(2):207-14. PubMed ID: 21913422
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Pathophysiological relevance of peroxisome proliferators activated receptors (PPAR) to joint diseases - the pro and con of agonists].
    Jouzeau JY; Moulin D; Koufany M; Sebillaud S; Bianchi A; Netter P
    J Soc Biol; 2008; 202(4):289-312. PubMed ID: 19094928
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Peroxisome proliferator-activated receptors and the metabolic syndrome.
    Bragt MC; Popeijus HE
    Physiol Behav; 2008 May; 94(2):187-97. PubMed ID: 18191967
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.